Artikel ; Online: A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia.
The Journal of clinical investigation
2021 Band 131, Heft 24
Abstract: BackgroundAntibody-based strategies for COVID-19 have shown promise in prevention and treatment of early disease. COVID-19 convalescent plasma (CCP) has been widely used but results from randomized trials supporting its benefit in hospitalized patients ... ...
Abstract | BackgroundAntibody-based strategies for COVID-19 have shown promise in prevention and treatment of early disease. COVID-19 convalescent plasma (CCP) has been widely used but results from randomized trials supporting its benefit in hospitalized patients with pneumonia are limited. Here, we assess the efficacy of CCP in severely ill, hospitalized adults with COVID-19 pneumonia.MethodsWe performed a randomized control trial (PennCCP2), with 80 adults hospitalized with COVID-19 pneumonia, comparing up to 2 units of locally sourced CCP plus standard care versus standard care alone. The primary efficacy endpoint was comparison of a clinical severity score. Key secondary outcomes include 14- and 28-day mortality, 14- and 28-day maximum 8-point WHO ordinal score (WHO8) score, duration of supplemental oxygenation or mechanical ventilation, respiratory SARS-CoV-2 RNA, and anti-SARS-CoV-2 antibodies.ResultsEighty hospitalized adults with confirmed COVID-19 pneumonia were enrolled at median day 6 of symptoms and day 1 of hospitalization; 60% were anti-SARS-CoV-2 antibody seronegative. Participants had a median of 3 comorbidities, including risk factors for severe COVID-19 and immunosuppression. CCP treatment was safe and conferred significant benefit by clinical severity score (median [MED] and interquartile range [IQR] 10 [5.5-30] vs. 7 [2.75-12.25], P = 0.037) and 28-day mortality (n = 10, 26% vs. n = 2, 5%; P = 0.013). All other prespecified outcome measures showed weak evidence toward benefit of CCP.ConclusionTwo units of locally sourced CCP administered early in hospitalization to majority seronegative participants conferred a significant benefit in clinical severity score and 28-day mortality. Results suggest CCP may benefit select populations, especially those with comorbidities who are treated early.Trial RegistrationClinicalTrials.gov NCT04397757.FundingUniversity of Pennsylvania. |
|||||
---|---|---|---|---|---|---|
Mesh-Begriff(e) | Adult ; Aged ; Antibodies, Viral ; COVID-19/therapy ; Female ; Hospitalization ; Humans ; Immune Tolerance ; Immunization, Passive/methods ; Immunosuppression Therapy ; Incidence ; Male ; Middle Aged ; Oxygen/therapeutic use ; Pneumonia, Viral/therapy ; RNA, Viral ; Respiration, Artificial ; Risk Factors ; SARS-CoV-2 ; Treatment Outcome ; COVID-19 Serotherapy | |||||
Chemische Substanzen | Antibodies, Viral ; RNA, Viral ; Oxygen (S88TT14065) | |||||
Sprache | Englisch | |||||
Erscheinungsdatum | 2021-11-17 | |||||
Erscheinungsland | United States | |||||
Dokumenttyp | Journal Article ; Randomized Controlled Trial | |||||
ZDB-ID | 3067-3 | |||||
ISSN | 1558-8238 ; 0021-9738 | |||||
ISSN (online) | 1558-8238 | |||||
ISSN | 0021-9738 | |||||
DOI | 10.1172/JCI155114 | |||||
Signatur |
|
|||||
Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Zusatzmaterialien
Kategorien
Verfügbar in ZB MED Köln/Königswinter
Ua VI Zs.184: Hefte anzeigen | Standort: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.